| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.21 | 0.0009 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.19 | 0.04 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.19 | 1e-08 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.19 | 6e-05 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.19 | 0.002 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | -0.17 | 0.0003 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | -0.17 | 2e-06 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.17 | 5e-07 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.16 | 0.02 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.03 |